Literature DB >> 12821324

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

Stefan Foser1, Alfred Schacher, Karl A Weyer, Doris Brugger, Elke Dietel, Stefan Marti, Thomas Schreitmüller.   

Abstract

Interferon alpha-2a plays an essential role in the treatment of chronic hepatitis C, but it is limited in its efficacy by the short in vivo half-life. To improve the half-life and efficacy, interferon alpha-2a is conjugated with a 40-kDa branched polyethylene glycol moiety (PEG-IFN, PEGASYS). From this preparation the positional PEG-IFN isomers were isolated and characterized by different analytical methods and antiviral assay. Two chromatographic steps were used to separate and purify nine isomers. The analytical methods IE-HPLC, RP-HPLC, SE-HPLC, SDS-PAGE, and MALDI-TOF MS indicated that each of these nine isomers is conjugated to the branched polyethylene glycol chain at a specific lysine. No isomer with a modification at the amino terminus was observed. All positional isomers induced viral protection of MDBK cells in the antiviral assay. When comparing the quantitative potency of the individual isomers with the whole mixture of PEG-IFN, significant differences in the specific activities were observed: PEG-Lys(31) and PEG-Lys(134) showed higher activities than the mixture, PEG-Lys(164) was equal to the mixture, whereas the activities of PEG-Lys(49), PEG-Lys(70), PEG-Lys(83), PEG-Lys(112), PEG-Lys(121), and PEG-Lys(131) were lower.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821324     DOI: 10.1016/s1046-5928(03)00055-x

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  22 in total

1.  Optimized clinical performance of growth hormone with an expanded genetic code.

Authors:  Ho Cho; Tom Daniel; Ying Ji Buechler; David C Litzinger; Zhenwei Maio; Anna-Maria Hays Putnam; Vadim S Kraynov; Bee-Cheng Sim; Stuart Bussell; Tsotne Javahishvili; Sami Kaphle; Guillermo Viramontes; Mike Ong; Stephanie Chu; G C Becky; Ricky Lieu; Nick Knudsen; Paola Castiglioni; Thea C Norman; Douglas W Axelrod; Andrew R Hoffman; Peter G Schultz; Richard D DiMarchi; Bruce E Kimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

Review 2.  Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Guanbo Wang; Burcu Baykal; Shunhai Wang
Journal:  Biotechnol Adv       Date:  2011-05-17       Impact factor: 14.227

3.  Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS.

Authors:  Xiaojun Lu; P Clayton Gough; Michael R DeFelippis; Lihua Huang
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-25       Impact factor: 3.109

4.  The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.

Authors:  Eleanor N Fish; Stephen A Harrison; Tarek Hassanein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

5.  PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.

Authors:  Jose Ramon; Vivian Saez; Reynier Baez; Raymersy Aldana; Eugenio Hardy
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

6.  PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.

Authors:  Lisa M Kaminskas; David B Ascher; Victoria M McLeod; Marco J Herold; Caroline P Le; Erica K Sloan; Christopher J H Porter
Journal:  J Control Release       Date:  2013-03-15       Impact factor: 9.776

7.  Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore.

Authors:  Ki Su Kim; Hoon Hyun; Jeong-A Yang; Min Young Lee; Hyemin Kim; Seok-Hyun Yun; Hak Soo Choi; Sei Kwang Hahn
Journal:  Biomacromolecules       Date:  2015-08-18       Impact factor: 6.988

8.  Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy.

Authors:  Christine A White; Jian-Guo Zhang; Lois A Salamonsen; Manuel Baca; W Douglas Fairlie; Donald Metcalf; Nicos A Nicola; Lorraine Robb; Evdokia Dimitriadis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

Review 9.  Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.

Authors:  Graham R Foster
Journal:  Drugs       Date:  2010       Impact factor: 9.546

10.  The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.

Authors:  Seyed Moayed Alavian; Bita Behnava; Seyed Vahid Tabatabaei
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.